Dialyzer expiration dating to be discussed at upcoming FDA/industry meeting.
This article was originally published in The Gray Sheet
DIALYZER EXPIRATION DATING TO BE DISCUSSED AT UPCOMING MEETING between FDA and manufacturers, agency staffers say. Although it does not expect to come forward with a formal proposal to require expiration dating on all dialyzers, FDA would like to explore the issue with manufacturers at the meeting. The agenda for the session is being finalized and a meeting date has not been set.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.